GLUT3 chimeric antigen receptor T cells

GLUT3 chimeric antigen receptor T cells are an investigational cell therapy engineered to overcome the metabolic restrictions of the tumor microenvironment (TME), specifically in glioblastoma (GBM). In solid tumors, massive glucose consumption by malignant cells creates a glucose-deficient environment that impairs the effector function and persistence of infiltrating CAR-T cells. These cells are modified to express GLUT3 (Solute carrier family 2, facilitated glucose transporter member 3), a high-affinity glucose transporter that restores metabolic fitness, cytokine production, and cytotoxic activity. To avoid the exhaustion and toxicity associated with continuous GLUT3 expression, an "on-demand" system was developed where GLUT3 transcription is driven by the nuclear translocation of NFAT (nuclear factor of activated T-cells) only upon target antigen stimulation. This approach enhances antitumor efficacy and long-term tumor control in preclinical models while minimizing adverse events and neurotoxicity.

Other names

On-demand GLUT3 CAR-T cellsNFAT-driven GLUT3 CAR-T cellsGLUT3-modified CAR-T cellsGLUT-3-modified CAR-T cellsGLUT 3-modified CAR-T cells